Synlab Group Selects Bruker´s MALDI Biotyper System for MS-based Molecular Microbial Identification
News Dec 03, 2009
At the KMIS meeting on Dec. 3-5, 2009 in Berlin, Bruker Daltonics announces a framework agreement with Synlab concerning molecular microbial identification based on MALDI-TOF mass spectrometry.
Synlab and Bruker have concluded a long-term partnership agreement in order to equip the laboratories of the Synlab association exclusively with the MALDI Biotyper system for molecular microbial identification.
The MALDI Biotyper is currently already in routine use in Synlab’s clinical microbiology centers in Trier, Weiden and Dachau in Germany. Moreover, Bruker and Synlab intend to further enlarge and refine the MALDI Biotyper reference library using well defined clinical isolates from the daily microbiology routine work of the Synlab laboratories.
The MALDI Biotyper is integrated into the Synlab laboratories’ microbiology workflow, combining fast molecular identification with conventional antibiotic susceptibility testing (AST). The MALDI Biotyper reports the identification results into the existing laboratory information systems (LIS). Integration with LIS MCS, Medat and Vision4health has already been established for Synlab, while integration with other LIS providers is also possible.
Dr. Ulrich Knipp, Technical Head of Microbiology at Synlab in Trier, commented: “After evaluating the MALDI Biotyper very thoroughly within the Synlab group, we are convinced that Bruker Daltonics is the most reliable partner for microbial identification based on mass spectrometry, and is providing outstanding microbiological service and support. Bruker Daltonics is fully established in the clinical microbiology market, and the MALDI Biotyper fulfils our requirements for reliability and robustness. The MALDI Biotyper represents a clear milestone substantiating our high quality molecular microbiology diagnostics.”
Missing Link Between Blow Flies and Possible Pathogen TransmissionNews
Determining whether blow flies have consumed animal fecal material versus animal tissue has important implications for both human public health and animal conservation. A recent study shows how that determination can be made.READ MORE
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE